Novartis AG





Real-time Estimate Cboe Europe 07:49:29 2024-06-21 EDT 5-day change 1st Jan Change
94.16 CHF -0.19% Intraday chart for Novartis AG -0.73% +11.13%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Factbox-European companies cut jobs as economy sputters RE
Dpa-AFX Overview: COMPANIES from 20/06/2024 - 15:15 DP
Novartis: towards the filing of a buyout offer for MorphoSys CF
MorphoSys Set to Delist Following Acquisition by Novartis MT
MorphoSys Inks Delisting Agreement After Takeover by Novartis MT
Biotech company Morphosys will soon disappear from the stock exchange RE
EU regulator mandates label updates on CAR-T cancer therapies RE
PeptiDream and Novartis Agreement Becomes Effective with 28.3 Billion Yen Upfront Payment MT
Nkarta, Inc. Appoints George Vratsanos as Board of Directors CI
Novartis' Fabhalta Shows Promise in Addressing Critical Gaps in C3 Glomerulopathy Treatment CI
NOVARTIS AG : JP Morgan reiterates its Neutral rating ZD
Abu Dhabi, Novartis to Collaborate on Genomics Research for Cancer Therapy MT
Novartis, Roche's Genentech Among Companies Facing Italian Competition Watchdog Inquiry Over Eye Drug MT
AlphaValue/Baader Europe Lowers Price Target on Novartis, Maintains Add Recommendation MT
Staff at drugmaker under U.S. scrutiny worked with Chinese military scientists RE
Novartis, Roche, Biogen, Samsung Bioepis in Italy Eye-Medicine Probe DJ
Novartis and others face Italy antitrust probe over eye drug RE
Three newcomers to the MDax - Rational, TUI and Traton move up RE
Cytokinetics CEO Says Board Would Have Backed Actionable Buyout DJ
The odds of rates getting cut in 2024 may be better than you think Our Logo
NOVARTIS AG : Deutsche Bank maintains a Buy rating ZD
Bank Vontobel Lifts Price Target on Novartis, Maintains Buy Recommendation MT
NOVARTIS AG : JP Morgan remains Neutral ZD
NOVARTIS AG : Buy rating from Goldman Sachs ZD
NOVARTIS : UBS reiterates buy recommendation after ASCO CF
Chart Novartis AG
More charts
Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales (excluding discontinued operations) break down by therapeutic area as follows: - oncology (29.9%); - immunology (17.2%); - cardiovascular, renal and metabolic diseases (14.1%); - neuroscience (8.9%). The remaining net sales (29.9%) are from contract manufacturing of pharmaceutical products. At the end of 2023, Novartis AG had 33 production sites worldwide. Net sales are distributed geographically as follows: Europe (33%), the United States (39.5%), Asia/Africa/Australasia (20.5%), Canada and Latin America (7%).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Mean consensus
Number of Analysts
Last Close Price
105.9 USD
Average target price
110.3 USD
Spread / Average Target
  1. Stock Market
  2. Equities
  3. NOVN Stock
  4. News Novartis AG
  5. Novartis AG to Acquire Mariana Oncology